Cellular actions of the insulin-like growth factor binding proteins.

By S. Firth, R. Baxter. Endocrine reviews, 2002

1,874 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Insulin and insulin-like growth factor signalling in neoplasia (2008, background): “In general, IGFBPs limit IGF access to IGF1R, thereby attenuating the bioactivity of these growth factor”
Sarcopenia: etiology, clinical consequences, intervention, and assessment (2009, background): “IGF-1 binds to receptors on skeletal muscle cell surfaces and activates a complex array of cell signaling pathways which are anabolic, anticatabolic, and antiapoptotic [37].”
Insulin-like growth factors and neoplasia (2004, background): “Bioavailability of IGFs is influenced by concentrations of specific IGFBP”
The insulin and insulin-like growth factor receptor family in neoplasia: an update (2012, background): “An additional level of control of IGF biological activity is provided by the family of high-affinity IGF-binding proteins (IGFBPs”
Senescence-messaging secretome: SMS-ing cellular stress (2009, background): “IGFBPs sequester IGFs and thereby suppress IGF-dependent signallin”
The many faces of insulin-like peptide signalling in the brain (2012, background): “Their main role is to exert tight control over IGF bioavailability, because IGFBPs bind IGFs with a higher affinity than do IGF receptor”
Circulating Insulin-Like Growth Factor I Mediates Effects of Exercise on the Brain (2000, background): “The CSF contains IGFs and IGF-binding proteins (IGFBPs) (Ferry et al., 1999).”